This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hu, J. C. Articles by Kamalati, T. Search for Related Content PubMed PubMed Citation Articles by Hu, J. C. Articles by Kamalati, T.

A Novel HSV-1 Virus, JS1/34.5^–/47^–, Purges Contaminating Breast Cancer Cells From Bone Marrow

Authors' Affiliations: ¹ Department of Oncology, Cancer Cell Biology Section; ² Department of Haematology, Imperial College Faculty of Medicine, Imperial College; ³ Department of Immunology and Molecular Pathology, The Windeyer Institute, University College London; ⁴ FACS Laboratory, Lincoln's Inn Fields Laboratories, London Research Institute, Cancer Research UK, London, United Kingdom; and ⁵ Biovex Ltd., Oxford, United Kingdom

Requests for reprints: Tahereh Kamalati, Department of Oncology, Cancer Cell Biology Section, Imperial College, Du Cane Road, London W12 ONN, United Kingdom. Phone: 44-208-383-8043; Fax: 44-208-383-5830; E-mail: t.kamalati{at}imperial.ac.uk.

Purpose: Oncolytic herpes simplex virus type 1 (HSV-1) vectors show considerable promise as agents for cancer therapy. We have developed a novel recombinant HSV-1 virus (JS1/34.5^–/47^–) for purging of occult breast cancer cells from bone marrow of patients. Here, we evaluate the therapeutic efficacy of this oncolytic virus.

Experimental Design: Electron microscopy was used to determine whether human breast cancer and bone marrow cells are permissive for JS1/34.5^–/47^– infection. Subsequently, the biological effects of JS1/34.5^–/47^– infection on human breast cancer cells and bone marrow were established using cell proliferation and colony formation assays, and the efficiency of cell kill was evaluated. Finally, the efficiency of JS1/34.5^–/47^– purging of breast cancer cells was examined in cocultures of breast cancer cells with bone marrow as well as bone marrow samples from high-risk breast cancer patients.

Results: We show effective killing of human breast cancer cell lines with the JS1/34.5^–/47^– virus. Furthermore, we show that treatment with JS1/34.5^–/47^– can significantly inhibit the growth of breast cancer cell lines without affecting cocultured mononuclear hematopoietic cells. Finally, we have found that the virus is effective in destroying disseminated tumors cells in bone marrow taken from breast cancer patients, without affecting the hematopoietic contents in these samples.

Conclusion: Collectively, our data show that the JS1/34.5^–/47^– virus can selectively target breast cancer cells while sparing hematopoietic cells, suggesting that JS1/34.5^–/47^– can be used to purge contaminating breast cancer cells from human bone marrow in the setting of autologous hematopoietic cell transplantation.

This article has been cited by other articles:

				N. S. Markovitz The Herpes Simplex Virus Type 1 UL3 Transcript Starts within the UL3 Open Reading Frame and Encodes a 224-Amino-Acid Protein J. Virol., October 1, 2007; 81(19): 10524 - 10531. [Abstract] [Full Text] [PDF]